US20200140481A1 - Preparation of biologically active complexes - Google Patents

Preparation of biologically active complexes Download PDF

Info

Publication number
US20200140481A1
US20200140481A1 US16/612,272 US201816612272A US2020140481A1 US 20200140481 A1 US20200140481 A1 US 20200140481A1 US 201816612272 A US201816612272 A US 201816612272A US 2020140481 A1 US2020140481 A1 US 2020140481A1
Authority
US
United States
Prior art keywords
seq
biologically active
salt
peptide
canceled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/612,272
Other languages
English (en)
Inventor
Aftab NADEEM
Catharina Svanborg
Chin Shing Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamlet Pharma AB
Original Assignee
Hamlet Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamlet Pharma AB filed Critical Hamlet Pharma AB
Assigned to HAMLET PHARMA AB reassignment HAMLET PHARMA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HO, Chin Shing
Assigned to HAMLET PHARMA AB reassignment HAMLET PHARMA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SVANBORG, CATHARINA
Assigned to HAMLET PHARMA AB reassignment HAMLET PHARMA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NADEEM, Aftab
Publication of US20200140481A1 publication Critical patent/US20200140481A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to methods for preparing biologically active complexes that have therapeutic activity in particular in the treatment of tumours or as antibacterial or antiviral agents.
  • the present invention further relates to methods of treating tumors and cancers, in particular to methods for selectively targeting tumor cells in preference to healthy cells, as well as to novel complexes and compositions for use in these methods.
  • tumour cells which means that they may give rise to therapeutic potential.
  • the unfolded proteins are frequently modified in some way, and in particular may be bound to cofactors such as fatty acid cofactors.
  • the complexes formed in this way may be stable and give rise to therapeutic options.
  • HAMLET human alpha-lactalbumin made lethal to tumor cells
  • HAMLET is one such example of a new family of tumoricidal molecules, with remarkable properties. Formed from partially unfolded ⁇ -lactalbumin and with oleic acid as an integral constituent, HAMLET was discovered by serendipity when studying the ability of human milk to prevent bacteria from binding to cells. Early in vitro experiments showed that HAMLET displays broad anti-tumor activity with a high degree of tumor selectivity and subsequent therapeutic studies have confirmed HAMLET's tumoricidal activity and relative selectivity for tumor tissue in vivo.
  • HAMLET topical HAMLET administration removed or reduced the size of skin papillomas and in patients with bladder cancer, local instillations of HAMLET caused rapid death of tumor cells but not of healthy tissue surrounding the tumor.
  • Therapeutic efficacy of HAMLET in bladder cancer was recently demonstrated in a murine bladder cancer model and HAMLET treatment delayed tumor progression and led to increased survival in a rat glioblastoma xenograft model without evidence of cell death in healthy brain tissue.
  • HAMLET thus appears to identify death pathways that are conserved in tumor cells, thereby distinguishing them from healthy, differentiated cells.
  • Procedures of this type have been used to produce other biologically active complexes including BAMLET, from bovine alpha-lactalbumin, and complexes formed from recombinant forms of alpha-lactalbumin, in particular those without cysteine residues as described in WO 2010/079362.
  • BAMLET is prepared in a one-phase system, in which ⁇ -lactalbumin is reconstituted in phosphate buffered saline (PBS) and sodium oleate added. The mixture is then heated to temperatures at or above 60° C. and active complex obtained.
  • PBS phosphate buffered saline
  • This method has the advantage of being simple to carry out, and may even be carried out in-situ in a clinical situation with the assistance of kits.
  • biologically active complex is prepared by dissolution of previously lyophilized complex in PBS (see for example WO2010/079362) for use.
  • Phosphate buffered saline as used previously, comprises a mixture of at least three and sometimes four salts. These are sodium chloride, disodium phosphate and mono-potassium phosphate, as well as in some cases also, potassium chloride.
  • a biologically active complex comprising dissolving a mixture of a polypeptide element in powder form and oleic acid or a pharmaceutically acceptable salt thereof also in solid form, in an aqueous solvent comprising at least two salts, the first of which is sodium or potassium chloride and the second of which is disodium phosphate or mono-potassium phosphate, wherein, in particular, the method is carried out at moderate temperature.
  • the expression ‘moderate temperature’ refers to temperatures of up to 50° C., for example from 0-50° C., for example from 10-40° C., and more particularly from 15-25° C., such as at ambient temperature. Such temperatures are generally below the ‘melt temperature’ at which the polypeptides become unfolded or denatured. However, the applicants have found that they are still able to form biologically active complexes under these salt conditions.
  • active complex can be prepared which shows a clear dose-dependent response, by the simple dissolution method of the invention.
  • the mixture may be warmed for example to temperatures of up to 50° C., such as up to 40° C. to achieve rapid dissolution, there is no need to heat the solution extensively such as described in by boiling, provided only that a suitable salt balance is present in the aqueous solvent.
  • the method is carried out at ambient temperature.
  • Dissolution may be facilitated by agitation, for example by vortexing. If required, the solution may be filtered through a sterile filter at this stage. Suitable filters include polyethersulfone membranes (PES) or Minisart® NML Cellulose acetate membranes.
  • any such agitation processes will be carried out for a period of time sufficient to ensure the dissolution of the elements in the salt solution.
  • the precise timings may vary depending upon factors such as the particular nature of the polypeptide being used and the temperature at which the mixture is held, the timings will typically be quite short, for example no more than 10 minutes, for example from 1-5 minutes such as about 2 minutes.
  • the solvent further comprises a third salt which is mono-sodium or mono-potassium phosphate, and in particular is mono-potassium phosphate.
  • a third salt which is mono-sodium or mono-potassium phosphate, and in particular is mono-potassium phosphate.
  • This method is therefore easy to prepare in a variety of manufacturing and non-manufacturing environments.
  • polypeptide used herein includes proteins and peptides including long peptides.
  • Suitable “polypeptide elements” for use in the method of the invention include naturally-occurring proteins, in particular alpha-lactalbumin, lysozyme or other proteins having a membrane perturbing activity, recombinant proteins and in particular variants of said naturally-occurring proteins which lack intra-molecular bonds for example as a result of mutation of cysteine residues, or in particular, fragments of any of these proteins, in particular peptides of up to 50 amino acids.
  • variant refers to proteins or polypeptides having a similar biological function but in which the amino acid sequence differs from the base sequence from which it is derived in that one or more amino acids within the sequence are substituted for other amino acids.
  • Amino acid substitutions may be regarded as “conservative” where an amino acid is replaced with a different amino acid with broadly similar properties. Non-conservative substitutions are where amino acids are replaced with amino acids of a different type.
  • conservative substitution is meant the substitution of an amino acid by another amino acid of the same class, in which the classes are defined as follows:
  • Nonpolar A, V, L, I, P, M, F, W Uncharged polar: G, S, T, C, Y, N, Q Acidic: D, E Basic: K, R, H.
  • altering the primary structure of a peptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This is so even when the substitution is in a region which is critical in determining the peptide's conformation.
  • Non-conservative substitutions are possible provided that these do not interrupt the function of the DNA binding domain polypeptides.
  • Determination of the effect of any substitution is wholly within the routine capabilities of the skilled person, who can readily determine whether a variant polypeptide retains the fundamental properties and activity of the basic protein.
  • the skilled person will determine whether complexes comprising the variant retain biological activity (e.g tumour cell death) of complexes formed with unfolded forms of the native protein and the polypeptide has at least 60%, preferably at least 70%, more preferably at least 80%, yet more preferably 90%, 95%, 96%, 97%, 98%, 99% or 100% of the native protein.
  • Variants of the polypeptide may comprise or consist essentially of an amino acid sequence with at least 70% identity, for example at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 96%, 97%, 98% or 99% identity to a native protein sequence such as an alphalactalbumin or lysozyme sequence.
  • the level of sequence identity is suitably determined using the BLASTP computer program with the native protein sequences as the base sequence. This means that native protein sequences form the sequence against which the percentage identity is determined.
  • the BLAST software is publicly available at http://blast.ncbi.nlm.nih.gov/Blast.cgi (accessible on 10 May 2017).
  • the polypeptide element is a peptide that has no more than 50 amino acids, and in particular may have from 10-45 amino acids.
  • Such complexes are easier to prepare and the starting materials are less costly.
  • peptides may be prepared using conventional methods for the production of peptides.
  • the complexes formed may be easier to handle and formulate for administration, due to the smaller molecular weight.
  • Suitable proteins are those identified as being active in such complexes, such as alpha-lactalbumin, beta-lactoglobulin or lysozyme, but may be derived from any membrane perturbing proteins.
  • Membrane perturbing proteins are proteins which have the capability of interacting with the interface of cell membranes, in particular causing disruption such as tubulation of the cell membrane. Typically, the protein will become embedded in the cell membrane.
  • coat complexes such as COPI, COPII (such as SAR 1), HOPS/CORVET, SEA (Sehl-associated), and clathrin complexes BAR domain proteins such as endophilins, and the ESCRT complex, including Snf7 domain subunits.
  • the peptide is derived from the alpha-helical domain of a naturally occurring protein as described above.
  • the alpha-helical domain of said proteins would be well understood in the art or may be determined using conventional methods.
  • alpha-helical domain contains a cysteine residue
  • these may, in some embodiments, be modified to a different amino acid residue, such as an alanine residue, in order to avoid inter-molecular disulphide bonds.
  • the peptide is a fragment of alpha-lactalbumin and specifically a fragment of the alpha domain of alpha-lactalbumin.
  • the peptide comprises amino acids of the Alpha 1 (residues 1-40) or Alpha 2 (residues 81-123) of human alpha-lactalbumin, or analogous regions of other alphalactalbumins such as bovine alpha-lactalbumin.
  • the peptide suitably contains no elements that give rise to folding and therefore suitably lacks amino acids that give rise to intramolecular bonding such as cysteine residues.
  • cysteine residues are replaced by other amino acids such as alanine.
  • the complex comprises amino acids of the Alpha 1 (residues 1-40) or Alpha 2 (residues 81-123) of human alpha-lactalbumin wherein the cysteines are replaced with other amino acids such as alanine, to prevent any intra-molecular bonding.
  • peptide may be of SEQ ID NO 1 or SEQ ID NO 2
  • sequences are those of SEQ ID NO 3 or SEQ ID NO 4.
  • the peptides of SEQ ID NO 1 may be truncated, for example by omitting the terminal alanine residue, resulting in a peptide of SEQ ID No 6, of which SEQ ID NO 7 is a specific example.
  • Such peptides are novel and form a further aspect of the invention, together with biologically active complexes comprising them.
  • peptides may also be used in the complex and the suitability may be tested by determining whether complexes with a fatty acid salt are active, for instance in killing cells using methods as described hereinafter.
  • the peptide is derived from a COPII family protein such as SAR1.
  • a COPII family protein such as SAR1.
  • a particular example of such a peptide is a peptide of SEQ ID NO 5 MAGWDIFGWF RDVLASLGLW NKH (SEQ ID NO 5).
  • the polypeptide element is a naturally-occurring protein or a synthetic form thereof, in particular an alpha-lactalbumin, such as human, bovine, sheep, camel or goat alpha-lactalbumin.
  • the protein is bovine lactalbumin.
  • biologically active means that the complex has a biological activity, which is different from - or stronger than the individual components.
  • the complex is able to induce cell death in particular selectively in tumour cells and/or has a bactericidal or antiviral effect not seen with the native protein including for example monomeric ⁇ -lactalbumin forms, although other therapeutic effects may be available.
  • oleic acid used in the method of the invention is C18:1 oleic acid of formula CH 3 (CH 2 ) 7 CH ⁇ CH(CH 2 ) 7 COOH or CH 3 (CH 2 ) 7 CH ⁇ CH(CH 2 ) 7 COO ⁇ .
  • a pharmaceutically acceptable salt of oleic acid is used in the process.
  • Suitable pharmaceutically acceptable salts would be understood in the art.
  • a salt and in particular a water-soluble salt of the oleic acid, fatty acid or lipid means that the preparation method is facilitated since aqueous solutions may be formed for instance for application to ion exchange columns and the like.
  • Suitable water-soluble salts are alkali or alkaline-earth metal salts such as sodium or potassium salts.
  • salts and in particular oleate salts such as sodium oleate appear to have some inherent tumoricidal effect. Therefore the inclusion of this in the complex may give rise to activity increases.
  • the first salt used in the method of the invention is sodium chloride.
  • the second salt used in the method of the invention is disodium phosphate.
  • the third salt used in the method of the invention is mono-potassium phosphate.
  • the ratio of first salt:second salt used in the method of the invention is suitably from 8:1 to 1:1, for example from 5:1 to 2:1 and in particular from 4:1 to 3.5:1.
  • the ratio of first salt:third salt is from 20:1 to 5:1, for example from 15:1 to 10:1 such as from 12.5:1 to 11.5:1.
  • the ratio of first to second to third salt is 13-12:4-3:1.
  • the ratio of oleic acid or oleate:peptide mixed in the method of the invention is suitably in the range of from 20:1 to 1 to 1, but preferably an excess of oleate is present, for instance in a ratio of oleate:peptide of about 5:1.
  • the mixing can be carried out at a temperature of from 0-50° C., conveniently at ambient temperature and pressure.
  • the product of the process of the invention may solidified for example by lyophilisation, for storage or for formulation purposes. Thereafter, it may be reconstituted using in particular, sterile water, for use. Such procedures may be particularly suitable where the polypeptide is a peptide rather than a protein. The applicants have found that proteins may revert to the natural folding state when subjected to procedures such as lyophilisation.
  • the problem may be alleviated by stabilising the polypeptide in the unfolded state, for example by lowering the pH of the solution, for instance to a value of 4 or less, or adding calcium chelators such as EDTA to the solvent during the preparation method.
  • the invention provides a complex obtainable by the method of the first aspect.
  • complexes of the second aspect of the invention may be formulated into useful pharmaceutical compositions by combining them with pharmaceutically acceptable carriers in the conventional manner.
  • Such compositions form a third aspect of the invention.
  • compositions in accordance with the third aspect of invention are suitably pharmaceutical compositions in a form suitable for topical use, for example as creams, ointments, gels, or aqueous or oily solutions or suspensions.
  • These may include the commonly known carriers, fillers and/or expedients, which are pharmaceutically acceptable.
  • Topical solutions or creams suitably contain an emulsifying agent for the protein complex together with a diluent or cream base.
  • the daily dose of the complex varies and is dependant on the patient, the nature of the condition being treated etc. in accordance with normal clinical practice. As a general rule from 2 to 200 mg/dose of the biologically active complex is used for each administration.
  • a method for treating cancer which comprises administering to a patient in need thereof, a biologically active complex as described above.
  • the complex may be used to treat cancers such as human skin papillomas, human bladder cancer and glioblastomas.
  • administration may be by infusion as is known in the art.
  • the invention further provides the biologically active complex as defined above for use in therapy, in particular in the treatment of cancer.
  • the complex may also be of use in the prevention of cancer, in particular gastrointestinal cancer as described for example in WO2014/023976.
  • the complex may be combined with a foodstuff, such as a dairy product such as yoghurt for use as a nutraceutical.
  • a foodstuff such as a dairy product such as yoghurt for use as a nutraceutical.
  • Compositions of this type form a further aspect of the invention.
  • FIG. 1A shows the results of ATP Lite, PrestoBlue and Trypan Blue studies obtained using a range of biologically active complexes, prepared in PBS, on tumour cells.
  • FIG. 1B shows results of ATP Lite, PrestoBlue and Trypan Blue studies obtained using a range of biologically active complexes, prepared in one salt of PBS, on tumour cells.
  • FIG. 1C presents results of ATP Lite, PrestoBlue and Trypan Blue studies obtained using a range of biologically active complexes, prepared in two salts of PBS, on tumour cells.
  • FIG. 2 shows a comparison of similar results obtained with and without filtration of the solutions.
  • FIG. 3A shows a schematic photograph of the preparation of a complex comprising bovine alpha-lactalbumin
  • FIG. 3B shows photographs of tubes before and after vortexing.
  • FIG. 4 shows results of ATP Lite, PrestoBlue and Trypan Blue studies of tumour cells to which the resultant solution was administered.
  • a range of biologically active complexes were prepared using a peptide of SEQ ID NO 7 Ac-KQFTKAELSQLLKDIDGYGGIALPELIATMFHTSGYDTQ-OH (SEQ ID NO 7)
  • the complexes obtained were then lyophilised.
  • the lyophilization conditions were a pressure below 1.2 mbar and a temperature below ⁇ 55° C.
  • Each tube was stored at ⁇ 20° C. or below and reconstituted by the addition of 30 mL sterile water shortly before use.
  • Human lung carcinoma cells (A549, ATCC) were cultured in RPMI-1640 with non-essential amino acids (1:100), 1 mM sodium pyruvate, 50 ⁇ g/ml Gentamicin and 5-10% fetal calf serum (FCS) at 37° C., 5% CO 2 .
  • FCS fetal calf serum
  • cells were grown on 96-well plate (2 ⁇ 10 4 /well, Tecan Group Ltd) overnight. Cells were incubated with biologically active complexes obtained in Example 1 at dosages equivalent to either 7, 21 or 35 ⁇ M peptide in serum-free RPMI-1640 at 37° C. FCS was added after 1 hour.
  • Cell death was quantified 3 hours after peptide-oleate treatment by three biochemical methods including 1) estimation of cellular ATP levels using luminescence based ATPliteTM kit (Perkin Elmer) 2) Presto Blue fluorescence staining (Invitrogen, A13262) and 3) trypan blue exclusion assay. Fluorescence and luminescence was measured using a microplate reader (Infinite F200, Tecan).
  • FIG. 1A-C The results are shown in FIG. 1A-C .
  • the complexes prepared in PBS were highly active and triggered cell death in a dose dependent manner ( FIG. 1A ).
  • Those prepared with only a single salt of the PBS ( FIG. 1B ) showed a significant loss of activity.
  • FIG. 1C the mixture (6) above, maintained a reasonable level of tumour cell death activity in a dose dependent manner.
  • Example 1 The method of example 1 was repeated twice using the PBS solution (1) but in this case, each solution was passed through a chemically different filter, either Polyethersulfone membranes (Ser. No. 12/846,445, VWR) and Minisart® NML cellulose acetate Filters (60/810,103, Sartorius).
  • a chemically different filter either Polyethersulfone membranes (Ser. No. 12/846,445, VWR) and Minisart® NML cellulose acetate Filters (60/810,103, Sartorius).
  • the biological efficacy of the product was tested as described in Example 2 in a side-by-side comparison with product which had not been filtered. The results are shown in FIG. 2 .
  • Bovine alpha-lactalbumin (700 ⁇ M), in lyophilised form, was added to a tube together with sodium oleate flakes (3.5 mM). Phosphate Buffered Saline (1 ml) was then added to the tube which was vortexed at room temperature for 1-2 minutes. A clear solution formed ( FIG. 3A-B )

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Water Supply & Treatment (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
US16/612,272 2017-05-14 2018-05-14 Preparation of biologically active complexes Abandoned US20200140481A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707715.7 2017-05-14
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes
PCT/EP2018/062396 WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/062396 A-371-Of-International WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/146,588 Division US12331073B2 (en) 2017-05-14 2021-01-12 Preparation of biologically active complexes

Publications (1)

Publication Number Publication Date
US20200140481A1 true US20200140481A1 (en) 2020-05-07

Family

ID=59201543

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/612,272 Abandoned US20200140481A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes
US17/146,588 Active US12331073B2 (en) 2017-05-14 2021-01-12 Preparation of biologically active complexes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/146,588 Active US12331073B2 (en) 2017-05-14 2021-01-12 Preparation of biologically active complexes

Country Status (13)

Country Link
US (2) US20200140481A1 (enrdf_load_stackoverflow)
EP (2) EP3811967B1 (enrdf_load_stackoverflow)
JP (2) JP7672122B2 (enrdf_load_stackoverflow)
KR (1) KR20200015557A (enrdf_load_stackoverflow)
CN (2) CN110650746B (enrdf_load_stackoverflow)
AU (1) AU2018269304B2 (enrdf_load_stackoverflow)
CA (1) CA3063285A1 (enrdf_load_stackoverflow)
DK (2) DK3618848T3 (enrdf_load_stackoverflow)
ES (2) ES2861252T3 (enrdf_load_stackoverflow)
FI (1) FI3811967T3 (enrdf_load_stackoverflow)
GB (1) GB201707715D0 (enrdf_load_stackoverflow)
PL (2) PL3618848T3 (enrdf_load_stackoverflow)
WO (1) WO2018210759A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331073B2 (en) 2017-05-14 2025-06-17 Hamlet Pharma Ab Preparation of biologically active complexes

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
US20220323391A1 (en) * 2019-08-20 2022-10-13 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
CN120239612A (zh) 2022-10-03 2025-07-01 林南制药公司 一种用于治疗或预防癌症的包含α-乳清蛋白和脂肪酸或脂质的复合物
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
AU2010204178B2 (en) 2009-01-09 2015-10-29 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
WO2012069836A2 (en) * 2010-11-24 2012-05-31 Hamlet Pharma Ab Biologically active complex and its preparation
ES2844874T3 (es) * 2012-08-09 2021-07-23 Hamlet Pharma Ab Complejo de proteína de leche y ácido graso
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331073B2 (en) 2017-05-14 2025-06-17 Hamlet Pharma Ab Preparation of biologically active complexes

Also Published As

Publication number Publication date
PL3811967T3 (pl) 2024-03-18
DK3618848T3 (da) 2021-03-01
DK3811967T5 (da) 2024-08-19
US20210130394A1 (en) 2021-05-06
JP2023075290A (ja) 2023-05-30
CN110650746B (zh) 2024-12-31
DK3811967T3 (da) 2024-01-08
EP3618848B1 (en) 2020-11-25
AU2018269304A1 (en) 2019-11-21
JP7705160B2 (ja) 2025-07-09
US12331073B2 (en) 2025-06-17
KR20200015557A (ko) 2020-02-12
EP3811967B1 (en) 2023-12-20
PL3618848T3 (pl) 2021-06-14
GB201707715D0 (en) 2017-06-28
EP3618848A1 (en) 2020-03-11
JP7672122B2 (ja) 2025-05-07
CN119700935A (zh) 2025-03-28
ES2973290T3 (es) 2024-06-19
CA3063285A1 (en) 2018-11-22
CN110650746A (zh) 2020-01-03
EP3811967A1 (en) 2021-04-28
JP2020519673A (ja) 2020-07-02
AU2018269304B2 (en) 2025-02-27
WO2018210759A1 (en) 2018-11-22
FI3811967T3 (fi) 2023-12-28
ES2861252T3 (es) 2021-10-06

Similar Documents

Publication Publication Date Title
US12331073B2 (en) Preparation of biologically active complexes
AU2008296733B2 (en) VEGFR-1/NRP-1 targeting peptides
CN107075574A (zh) 铁调素和微型铁调素类似物及其用途
US20160115200A1 (en) New Use for JNK Inhibitor Molecules for Treatment of Various Diseases
US20230372450A1 (en) Method for preparing a composition comprising an unfolded protein
Cárdenas-Martínez et al. Effects of substituting arginine by lysine in bovine lactoferricin derived peptides: pursuing production lower costs, lower hemolysis, and sustained antimicrobial activity
JP2021514183A (ja) 改変免疫調節ペプチド
JP2024504467A (ja) がん療法で使用するための乳酸脱水素酵素活性のポリペプチド阻害剤
US11566045B2 (en) Tumor targeting polypeptide and method of use thereof
HK40050699A (en) Preparation of biologically active complexes
HK40050699B (en) Preparation of biologically active complexes
HK40025666B (en) Biologically active complexes and therapeutic uses thereof
HK40025666A (en) Biologically active complexes and therapeutic uses thereof
EP3329930A1 (en) Pharmaceuctical compositions
WO1999065512A1 (fr) Compositions medicinales contenant des peptides apparentes au facteur de croissance des fibroblastes
TWI825397B (zh) 包含il-2蛋白及cd80蛋白的融合蛋白調配物
EP4183794A1 (en) Peptide, peptide salt, pharmaceutical composition and biological tissue calcification inhibitor
JP2023540800A (ja) リフォールディングされたヒト血清アルブミン及びその抗腫瘍ための使用
GB2574845A (en) Therapeutically active complexes
HK1164344A (en) Vegfr-1/nrp-1 targeting peptides

Legal Events

Date Code Title Description
AS Assignment

Owner name: HAMLET PHARMA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SVANBORG, CATHARINA;REEL/FRAME:050970/0183

Effective date: 20180426

Owner name: HAMLET PHARMA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HO, CHIN SHING;REEL/FRAME:050970/0153

Effective date: 20190826

Owner name: HAMLET PHARMA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NADEEM, AFTAB;REEL/FRAME:050970/0214

Effective date: 20180427

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION